HK1110030A1 - Lysis/resealing process and device for incorporating an active ingredient in erythrocytes - Google Patents

Lysis/resealing process and device for incorporating an active ingredient in erythrocytes

Info

Publication number
HK1110030A1
HK1110030A1 HK08101485.2A HK08101485A HK1110030A1 HK 1110030 A1 HK1110030 A1 HK 1110030A1 HK 08101485 A HK08101485 A HK 08101485A HK 1110030 A1 HK1110030 A1 HK 1110030A1
Authority
HK
Hong Kong
Prior art keywords
lysis
active ingredient
erythrocytes
resealing
suspension
Prior art date
Application number
HK08101485.2A
Other languages
English (en)
Inventor
Yann Godfrin
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34949346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1110030(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of HK1110030A1 publication Critical patent/HK1110030A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/06—Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08101485.2A 2004-08-05 2008-02-06 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes HK1110030A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408667A FR2873925B1 (fr) 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
PCT/IB2005/002323 WO2006016247A2 (en) 2004-08-05 2005-08-04 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes

Publications (1)

Publication Number Publication Date
HK1110030A1 true HK1110030A1 (en) 2008-07-04

Family

ID=34949346

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08101485.2A HK1110030A1 (en) 2004-08-05 2008-02-06 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes

Country Status (16)

Country Link
US (2) US8617840B2 (xx)
EP (2) EP2277594B1 (xx)
JP (1) JP4598827B2 (xx)
KR (1) KR101332733B1 (xx)
CN (1) CN101031339B (xx)
AT (1) ATE532504T1 (xx)
AU (1) AU2005270977B2 (xx)
CA (2) CA2575617C (xx)
DK (1) DK1773452T3 (xx)
ES (1) ES2376979T3 (xx)
FR (1) FR2873925B1 (xx)
HK (1) HK1110030A1 (xx)
PL (1) PL1773452T3 (xx)
PT (1) PT1773452E (xx)
SI (1) SI1773452T1 (xx)
WO (1) WO2006016247A2 (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
FR2891843A1 (fr) * 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
EP2041299A4 (en) 2006-07-14 2010-01-13 Aviva Biosciences Corp METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE
KR100828018B1 (ko) * 2006-11-20 2008-05-08 레인보우스케이프주식회사 수질정화용 여과재
AP2937A (en) * 2007-04-20 2014-07-31 Gen Hospital Corp Method for counting cells
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) * 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
WO2009101467A1 (en) * 2008-02-13 2009-08-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2938332B1 (fr) * 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
FR2940087B1 (fr) * 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
EP2199791B1 (de) * 2008-12-19 2019-05-01 F. Hoffmann-La Roche AG Verfahren zum Bestimmen der Hämolyse einer Blutprobe sowie Vorrichtung
FR2944106B1 (fr) * 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
PT2493487T (pt) * 2009-10-27 2016-11-08 Erytech Pharma Composição para induzir uma tolerância imunitária específica
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20120308985A1 (en) * 2011-04-21 2012-12-06 Streck, Inc. Immature Reticulocyte Fraction Reference Control and Related Methods
CN104394884A (zh) 2012-03-21 2015-03-04 爱瑞泰克药物公司 用于治疗急性髓细胞白血病(aml)的药剂
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
CA2911976C (en) * 2013-05-10 2021-01-19 Erydel S.P.A. Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
KR102530914B1 (ko) 2013-08-16 2023-05-11 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3107563B1 (en) 2014-02-21 2021-04-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
SG10201903912XA (en) 2014-10-31 2019-05-30 Massachusetts Inst Technology Delivery of biomolecules to immune cells
US11125739B2 (en) 2015-01-12 2021-09-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
EP3320082B1 (en) 2015-07-09 2023-05-24 Massachusetts Institute of Technology Delivery of materials to anucleate cells
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
HUE057660T2 (hu) 2016-01-11 2022-06-28 Rubius Therapeutics Inc Multimodális terápiás sejtrendszerekkel kapcsolatos készítmények és eljárások rákindikációkra
EP3452604A1 (en) * 2016-05-03 2019-03-13 SQZ Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance
LT3496743T (lt) 2016-08-08 2022-04-11 Aerase, Inc. Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
EP3449935A1 (en) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
JP2021505620A (ja) 2017-12-05 2021-02-18 イーレイズ・インコーポレーテッド アルギナーゼ１欠損症を治療するための方法及び組成物
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
CA3111126A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
EP3880309A1 (en) 2018-11-15 2021-09-22 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
US20220175319A1 (en) * 2019-04-01 2022-06-09 Given Imaging Ltd In vivo immunoassay system
EP4149440A1 (en) 2020-05-11 2023-03-22 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
US20220313798A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
WO2023027613A1 (ru) * 2021-08-27 2023-03-02 Общество С Ограниченной Ответственностью "Рбк-Фармэко" Устройство и способ для включения биологически активных компонентов в эритроциты способом проточного диализа
WO2023067200A1 (en) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer
WO2024015529A2 (en) 2022-07-14 2024-01-18 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740053A1 (de) 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPS5468291A (en) * 1977-11-10 1979-06-01 Mitsubishi Chem Ind Method of measuring osmotic pressure resistance of corpuscle membrane
US4327710A (en) * 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4478824A (en) * 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
US4801777A (en) * 1987-09-03 1989-01-31 Vanderbilt University Blood rewarming method and apparatus
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
KR960700740A (ko) * 1993-03-23 1996-02-24 라차아드 엘 콘 세포내 생물학적 활성 물질의 캡슐화 방법 및 장치(method and apparatus for encapsulation of biologic ally-active substances in cells)
DE69732225T2 (de) * 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
WO2002010177A1 (en) 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof

Also Published As

Publication number Publication date
US20140154797A1 (en) 2014-06-05
EP1773452B1 (en) 2011-11-09
EP2277594B1 (en) 2016-03-30
JP4598827B2 (ja) 2010-12-15
AU2005270977B2 (en) 2011-11-24
PT1773452E (pt) 2012-02-08
CN101031339A (zh) 2007-09-05
US8617840B2 (en) 2013-12-31
FR2873925B1 (fr) 2006-10-13
PL1773452T3 (pl) 2012-04-30
JP2008508920A (ja) 2008-03-27
KR20070058478A (ko) 2007-06-08
CA2575617A1 (en) 2006-02-16
US20080261262A1 (en) 2008-10-23
KR101332733B1 (ko) 2013-11-25
AU2005270977A1 (en) 2006-02-16
EP2277594A3 (en) 2011-05-18
FR2873925A1 (fr) 2006-02-10
US10273444B2 (en) 2019-04-30
WO2006016247A3 (en) 2006-06-22
CA2892729A1 (en) 2006-02-16
SI1773452T1 (sl) 2012-03-30
WO2006016247A2 (en) 2006-02-16
CA2892729C (en) 2017-05-09
CA2575617C (en) 2015-10-06
EP2277594A2 (en) 2011-01-26
ES2376979T3 (es) 2012-03-21
DK1773452T3 (da) 2012-02-27
CN101031339B (zh) 2012-07-18
ATE532504T1 (de) 2011-11-15
EP1773452A2 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
HK1110030A1 (en) Lysis/resealing process and device for incorporating an active ingredient in erythrocytes
Reddoch et al. Hemostatic function of apheresis platelets stored at 4 C and 22 C
Johnson et al. Refrigeration and cryopreservation of platelets differentially affect platelet metabolism and function: a comparison with conventional platelet storage conditions
Obrador et al. Red blood cell storage lesion
Pidcoke et al. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time
Reikvam et al. The Mirasol® Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution
JP7148499B2 (ja) 嫌気性血液貯蔵および病原体不活性化方法
Staikou et al. Impact of graded hypothermia on coagulation and fibrinolysis
Pallotta et al. Red blood cell processing for cryopreservation: from fresh blood to deglycerolization
WO2005072523A3 (en) Biological material and methods and solutions for preservation thereof
Hughes et al. Warm storage of whole blood for 72 hours
JP2002516254A (ja) ヒト赤血球の低温保存
ATE401539T1 (de) Kryoeinrichtung und zugehöriges betriebsverfahren
KR20160005077A (ko) 활성 성분을 캡슐화하는 적혈구의 현탁물을 안정화하는 방법, 수득되는 현탁물
Lelkens et al. Prolonged post‐thaw shelf life of red cells frozen without prefreeze removal of excess glycerol
Thomas Ambient overnight hold of whole blood prior to the manufacture of blood components
NasrEldin Effect of cold storage on platelets quality stored in a small containers: implications for pediatric transfusion
Skripchenko et al. A rest period before agitation may improve some in vitro apheresis platelet parameters during storage
Swärd‐Nilsson et al. Factors influencing factor VIII activity in frozen plasma
Arav et al. Freeze drying (lyophilization) of red blood cells
Rindler et al. Freeze-drying of red blood cells: how useful are freeze/thaw experiments for optimization of the cooling rate?
US20180168143A1 (en) Activated platelet preservation composition, method for preserving activated platelet and preserved activated platelet using the same
WO2011089391A1 (en) Mammalian cell preservation methods
Dijkstra‐Tiekstra et al. Comparison of various dimethylsulphoxide‐containing solutions for cryopreservation of leucoreduced platelet concentrates
AU2020372904A1 (en) Anaerobic blood storage and pathogen inactivation method